The main aim of the trial is to assess the long‑term safety of the study drug, meaning how well it is tolerated over time and what side effects may occur. Participants who have already finished earlier studies receive the medication for an extended period, attending regular visits where health checks, blood tests and simple scans are performed. Any unwanted problems, called adverse events, are recorded and evaluated, with particular attention to serious issues that might require medical care.

The treatment being studied involves a combination of two medications: MK-1084 and pembrolizumab. Pembrolizumab is also known by the brand name KEYTRUDA and is given as an infusion, which means it is delivered directly into the bloodstream through a vein. MK-1084 is taken as a tablet. Some participants in the study will receive pembrolizumab with MK-1084, while others will receive pembrolizumab with a placebo, which looks like the real medication but does not contain any active ingredients. The purpose of the study is to compare the effectiveness of these two treatment combinations.

Participants in the study will receive their assigned treatment and will be monitored over a period of time to see how their cancer responds. The study will look at how long participants live without their cancer getting worse, known as progression-free survival, and overall survival, which is the length of time participants live after starting the treatment. The study will also track any side effects experienced by participants and how the treatment affects their quality of life. This information will help researchers understand the potential benefits and risks of the new treatment combination for people with this specific type of lung cancer.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

The study is designed to continue treatment for patients who have already participated in previous research with rocatinlimab. Participants will receive either rocatinlimab or placebo through injections under the skin. This is a long-term study that will monitor how well patients maintain improvement in their skin condition and any side effects that may occur during treatment.

The research will track various aspects of the skin condition, including changes in skin appearance, itching severity, and overall symptoms. The study will particularly focus on monitoring the safety of the treatment by recording any side effects and checking laboratory test results and vital signs throughout the treatment period.

The purpose of the study is to evaluate safety and find the best dose of the new medicines when used alone or in combination. Participants receive an IV infusion, which means the medicine is delivered directly into a vein, and they swallow tablets on a regular schedule. Treatment cycles are repeated every few weeks, and patients return to the clinic for regular check‑ups, blood tests, and simple examinations to watch for any side effects.

Participants will receive the assigned tablet daily and the infusion every few weeks, with regular clinic visits for safety checks, blood tests and imaging scans such as CT scans to look for changes in tumor size. The study will continue until the disease gets worse, a participant stops treatment, or the trial ends. Researchers will record how long the cancer stays stable (progression‑free survival), overall survival, side effects, and quality‑of‑life questionnaires.

The purpose of the trial is to compare how well the new medicine works against the standard treatment in shrinking tumors and helping patients live longer. Participants will be randomly assigned to one of the two treatment arms and will receive the assigned therapy in repeated cycles every few weeks. Throughout the study, doctors will perform regular safety checks, blood tests, and imaging scans to see how the disease responds, and they will record any side effects that occur.

The purpose of the study is to see if the new combination can keep the cancer from getting worse for a longer time than the standard treatments. Participants are randomly assigned to receive either the new three‑drug regimen or the standard therapy, and they take the medicines in repeated cycles while visiting the clinic for regular check‑ups and imaging scans. The main result being measured is progression‑free survival (PFS), which means the time until the cancer grows or the patient dies, and it is evaluated using standard imaging rules called RECIST and analyzed with the Kaplan‑Meier statistical method. Safety and side‑effects are recorded and graded according to the CTCAE system.

Participants are assigned by chance to receive either EIK1001 with pembrolizumab and chemotherapy, or a placebo with pembrolizumab and chemotherapy. The study is done in different parts and includes two doses of EIK1001 to help find the best dose. Treatment is given over time, with regular study visits and follow-up while the cancer and side effects are watched.

The main purpose of the study is to compare how well the treatment combinations work and how safe they are. Progression-free survival means the time before the cancer gets worse or the person dies, and overall survival means the time before death from any cause. The study also looks at side effects and whether treatment has to be stopped because of them.

People in the study are assigned by chance to one of the two treatment groups, and neither the study team nor the participants know which treatment is being given. The treatment is taken as tablets over time, with regular study visits during the trial. During these visits, the study team checks for side effects and overall health, and asks about symptoms and daily well-being.

The trial is looking at adults with advanced kidney cancer who have already received treatment with PD-1/L1 and VEGF-TKI medicines, either one after the other or together. PD-1/L1 and VEGF-TKI are types of cancer medicines that act in different ways to slow tumor growth. The study follows participants while they receive treatment and for some time afterward to understand the effects of the medicine combination over time.

Participants in the study will be divided into two groups. One group will receive meropenem through an intravenous infusion, which is a method of delivering medication directly into a vein. The other group will receive a placebo consisting of sodium chloride, a common salt solution. This process is conducted as a double-blind trial, meaning neither the patients nor the medical staff know which substance is being administered during the treatment period.

During the course of the study, medical professionals will monitor how the body responds to the treatment. The focus will be on observing survival rates and checking for organ dysfunction, which refers to a situation where vital organs such as the kidneys, liver, or lungs are not working correctly. The study will also track how long patients remain in the hospital and the overall progress of the illness following the administration of the medication.

The purpose of the study is to determine whether the combination tablet provides better pain relief and is well tolerated compared with the single‑ingredient tablet and placebo. Over a period of about one week, participants take the assigned tablets at regular intervals and record their pain levels and any need for extra pain medication. Simple physical tests, such as reaching toward the floor, are performed at the start and at the end of the week to see if movement improves.

One group will receive sotorasib combined with a platinum doublet, which refers to a combination of two drugs like carboplatin and pemetrexed. The other group will receive pembrolizumab along with the same platinum doublet. Other medications, such as folic acid, hydroxocobalamin, dexamethasone, and antiemetics, may be used to support the treatment and manage side effects. During the study, the time until the cancer grows or worsens and the total length of time patients live are monitored.

The treatments involve medications administered through an Intravenous line, which is a method of delivering medicine directly into a vein. One group receives the study drug PF-08634404 along with a combination of chemotherapy drugs, which may include Paclitaxel, Carboplatin, or Pemetrexed. Another group receives Pembrolizumab combined with these chemotherapy drugs. Some participants may also receive Paclitaxel Albumin-Bound or a Placebo involving Sodium Chloride. During the study, participants will be monitored to see how they respond to the medicines and to track their Overall Survival and Progression-Free Survival, which refers to the length of time during and after treatment that a person lives with the disease without it getting worse.

The study consists of an initial phase to see how well the treatment works to control symptoms, followed by an extension period to continue monitoring the effects. During the study, medical professionals will monitor the levels of vixarelimab in the blood and check for anti-drug antibodies, which are substances the body might create in response to a medication. The course of the study involves regular assessments to observe changes in symptoms and the condition of the intestinal lining.

The study is designed to see which treatment approach helps patients live longer, which is referred to as overall survival. Other factors being looked at include progression-free survival, which is the length of time during and after treatment that a disease does not get worse, and the time it takes for a disease to begin growing again. The study also monitors how the body responds to the medicine and any changes in symptoms like cough, chest pain, or dyspnea, which is the medical term for shortness of breath.

During the trial, participants are assigned to different groups to receive either the combination of medicines or a single medicine. Researchers will track how the drugs affect the body and any adverse events, which are unexpected or unpleasant side effects that occur during treatment. The study will also examine the amount of medicine present in the blood and how the body’s health and quality of life change over time.

During the trial, participants will receive either tenecteplase or the standard of care via an intravenous bolus, which is a method of delivering medication directly into a vein in a single quick dose. The study will monitor how well patients recover and function over a period of time, specifically looking at their ability to perform daily activities 90 days after the event. The researchers will also observe for any potential side effects, such as symptomatic intracranial hemorrhage, which is a type of bleeding inside the brain that can occur following treatment.

The purpose of the study is to compare the effectiveness of different medication combinations in preventing the cancer from getting worse. One group will receive a combination of sotorasib, panitumumab, and FOLFIRI. FOLFIRI is a treatment plan that includes fluorouracil, irinotecan hydrochloride trihydrate, and calcium folinate, all of which are administered through intravenous use, meaning they are delivered directly into a vein. Another group will receive FOLFIRI either alone or combined with bevacizumab.

Participants will be assigned to one of these treatment groups to see which approach is better at managing the disease. The study will follow the progress of the cancer over time to observe how long the treatments keep the disease from spreading further or increasing in size.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

The study is divided into two phases. In the first phase, the focus is on determining the appropriate dose of Elacestrant when combined with Abemaciclib. In the second phase, the study aims to evaluate how effective this combination is in treating patients with brain metastases from this type of breast cancer. Participants will take the medications orally, and the study will monitor their response to the treatment over time.

Throughout the study, participants will be observed for any changes in their condition, including the size and number of brain metastases. The study will also track any side effects or adverse reactions to the medications. The goal is to gather information that could help improve treatment options for patients with this type of breast cancer in the future.

During the study, participants will take their assigned medications by mouth as tablets or capsules. They will continue their ongoing hormone therapy that lowers testosterone levels throughout the study. The study will track how long it takes for the cancer to get worse by using imaging scans, which are special pictures of the inside of the body taken with machines. The study team will also monitor various aspects of health, including blood tests to measure a substance called prostate-specific antigen, pain levels, quality of life, and any side effects that may occur. Participants will attend regular visits where doctors will perform examinations and tests to assess how the treatment is working and how participants are feeling.

The study will also look at other important measures such as how long participants live, whether tumors shrink in response to treatment, how long any tumor shrinkage lasts, and how long it takes before additional cancer treatments are needed. Doctors will carefully monitor for any unwanted effects of the medications and will check participants’ overall well-being through questionnaires about pain, tiredness, and daily functioning. Blood samples will be taken at certain times to measure the levels of mevrometostat in the body and to examine genetic material from cancer cells that may be circulating in the blood.

The purpose of this study is to find out if xaluritamig can help people live longer compared to the other treatment options. Xaluritamig is given as an infusion into a vein, which means it is delivered directly into the bloodstream through a needle. Some people in the study may also receive siltuximab, which is another medicine given through a vein that may help manage certain side effects. The study will also look at whether the cancer stops growing or shrinking, how long any improvements last, whether bone problems are delayed, and how the treatments affect pain and quality of life. Additionally, the study will monitor any unwanted effects or side effects that occur during treatment and will measure how the body processes xaluritamig and whether the body develops any immune response to it.

People joining this study will be randomly assigned to receive either xaluritamig or one of the other treatment options chosen by their doctor. Throughout the study, participants will have regular check-ups that include scans to see how the cancer is responding, blood tests to check overall health and levels of a substance called prostate-specific antigen, and questionnaires to understand how they are feeling and how the treatment is affecting their daily life. The study will continue for several years to gather enough information about how well the treatments work and how safe they are.

Patients in the study will be divided into different groups. Some groups will receive combinations of the study medications along with their standard care, while another group will receive only standard care. The medications will be given in different forms, including injections under the skin, injections into a vein, and liquids taken by mouth. Treatment will start within 36 hours after stroke symptoms begin and will continue for a certain period. During the study, patients will have regular check-ups and tests to see how they are doing.

The study will use brain imaging tests like CT scans and MRI to look at the brain and check for any bleeding or changes in the damaged area. Doctors will also measure how well patients can perform daily activities and check their stroke symptoms using special scoring systems. Blood tests will be done to measure medication levels and other substances in the blood. The study will also check for side effects, including whether patients develop depression, and will monitor overall safety throughout the treatment period.

The purpose of this study is to compare how well MK-2870 combined with pembrolizumab works compared to pembrolizumab alone in preventing the cancer from coming back after surgery. Before being assigned to one of these treatment groups, participants will first receive pembrolizumab along with platinum-based chemotherapy before surgery, which is called neoadjuvant treatment. After surgery, if cancer cells are still found in the removed tissue, meaning a complete response was not achieved, participants will then be randomly assigned to receive either MK-2870 plus pembrolizumab or pembrolizumab alone as adjuvant treatment, which means treatment given after surgery to reduce the risk of cancer returning.

During the study, participants will have regular check-ups that include imaging scans such as computed tomography or magnetic resonance imaging to monitor for any signs of cancer returning. The study will measure how long participants remain free of disease, how long they survive overall, and whether the cancer spreads to distant parts of the body. Researchers will also assess quality of life and monitor for any side effects throughout the treatment period. The treatment period can last up to several months, and participants will continue to be followed for a number of years to track long-term outcomes.

The purpose of this study is to find out if camizestrant, either alone or combined with abemaciclib, works better than standard hormone treatments, either alone or combined with abemaciclib, in preventing breast cancer from coming back. The study will measure how long people remain free from invasive breast cancer returning. People taking part in this study will be assigned by chance to receive either camizestrant or one of the standard hormone treatments. The treatment will continue for a period of time, and people will be monitored regularly to check how well the treatment is working and to watch for any unwanted effects.

During the study, doctors will check for any side effects that occur, perform blood tests, and measure vital signs like blood pressure and heart rate. People in the study will also be asked questions about their quality of life and how the side effects of treatment affect them in their daily lives. Blood samples may be taken to measure the amount of camizestrant in the blood. The study will track whether the cancer comes back, spreads to other parts of the body, or if a new cancer develops, as well as overall survival.

The study is divided into different parts for adults and adolescents. For adults, there is an induction phase and a maintenance phase. During the induction phase, the study will look at whether icotrokinra can help bring the disease under control compared to placebo. This part lasts 12 weeks. If participants respond well to the treatment during induction, they may continue into the maintenance phase, which lasts 40 weeks. During this time, the study will check if icotrokinra can keep the disease under control. For adolescents aged 12 to 17 years, the study focuses on the maintenance phase to see if icotrokinra can keep their condition under control after they have responded to the treatment.

Participants in this study will need to have been diagnosed with Ulcerative Colitis at least 12 weeks before joining. The study will involve regular assessments to measure how active the disease is and how well the treatment is working. The medication is given as a film-coated tablet taken by mouth. The study is expected to run for several years to gather information about the long-term effects of this treatment.

The study is divided into different phases to test how well the medication works. In the first phase, called the induction phase, the goal is to see if icotrokinra can help reduce symptoms and improve the condition of the intestines after about 12 weeks of treatment. The study will look at whether participants have fewer symptoms and whether the inflammation in their intestines has improved. In the second phase, called the maintenance phase, participants who responded well to the treatment will continue to receive either icotrokinra or placebo for a longer period, up to about 40 weeks. This phase will check if the medication can help keep the disease under control over time and prevent symptoms from coming back.

Participants in this study must be adults who have been diagnosed with Crohn’s Disease for at least 12 weeks before joining the study. They need to have active disease with symptoms such as frequent loose stools or abdominal pain, and this must be confirmed by an examination of the intestines that shows inflammation and ulcers. Participants should have previously tried other treatments for Crohn’s Disease, such as steroids or other medications including biologics, but these treatments either did not work well enough, stopped working over time, or caused problems that made them difficult to tolerate. The study will last several years and will involve regular visits to monitor how well the treatment is working and to check for any side effects.

The main goal of this study is to find out if zodasiran can reduce low-density lipoprotein cholesterol, commonly called bad cholesterol, compared to placebo in people with this genetic condition. The study will measure cholesterol levels in the blood after participants have not eaten, which is called fasting cholesterol. The researchers will look at various types of fats in the blood, including different forms of cholesterol and other substances that carry fats through the bloodstream.

The study will last approximately 12 months for the main treatment period. Participants will receive the study medication as an injection under the skin using a pre-filled syringe. The maximum dose that may be given is 200 milligrams at one time, with a total maximum dose of 2000 milligrams over the entire treatment period of 24 weeks. During the study, doctors will regularly check cholesterol levels and other measurements to see how well the treatment is working and to monitor for any side effects. The study includes both teenagers aged 12 years and older as well as adults who have been diagnosed with this inherited cholesterol condition.

The main purpose of this study is to compare how long people live when treated with the investigational medicine compared to docetaxel. The study will look at this in all people whose tumors have PD-L1 levels of at least one percent, and also specifically in those whose tumors have PD-L1 levels of fifty percent or higher. People taking part will be randomly assigned to receive either the investigational medicine or docetaxel. The study will also look at other things like how well the tumors respond to treatment, how long any response lasts, and what side effects occur with each treatment.

During the study, participants will receive their assigned treatment for up to sixty months. Those receiving the investigational medicine will get it at a dose based on their body weight, while those receiving docetaxel will get it at a dose based on their body surface area. The study team will regularly check how the cancer is responding to treatment and monitor for any side effects. Participants will also be asked about their quality of life and any symptoms they are experiencing. Blood samples will be taken from those receiving the investigational medicine to measure drug levels in the body and to check for immune responses to the medicine. Tumor tissue samples will also be collected for testing to help understand how the treatments work.

The purpose of this study is to see how well these treatment combinations work against the lung cancer in patients who have the specific EGFR mutations. The study will look at whether the treatments can slow down or stop the cancer from growing or spreading. Patients in the study will receive their assigned treatment combination and will be monitored regularly by the doctors to check how the cancer is responding and to watch for any side effects. The study is designed as an open-label trial, which means that both the patients and the doctors will know which treatment is being given.

During the study, patients will have regular visits where doctors will perform tests and examinations to measure the size of the cancer and see if it is getting smaller, staying the same, or growing. The study will follow patients for several years to gather information about how long the treatment keeps the cancer under control and how patients feel while taking the medications. This information will help doctors understand whether these treatment combinations could be useful options for patients with this type of lung cancer in the future.

The purpose of this study is to compare how well the combination of belzutifan and zanzalintinib works against cabozantinib in treating advanced kidney cancer. The study will look at how long people live without their cancer getting worse and how long they live overall. The study will also measure how many people respond to treatment, meaning their cancer shrinks or disappears, and how long that response lasts.

During the study, people will be randomly assigned to receive either the combination treatment or cabozantinib alone. The study will track any unwanted effects that occur and whether people need to stop treatment because of these effects. The study will also measure quality of life and how well people are able to carry out daily activities using questionnaires that ask about physical health, ability to perform usual activities, and symptoms related to kidney cancer. The study will continue to follow people over time to gather information about how the treatments affect their cancer and overall health.

People who join this study will have recently been hospitalized for a heart attack and will have had a procedure to look at the blood vessels in their heart. They will also have at least one additional risk factor, such as a previous heart attack, diabetes requiring medication, reduced kidney function, previous stroke, disease in the neck or leg arteries, or blockages in multiple heart arteries. The study medication will be started as soon as possible after the heart procedure, within a specific time window depending on the type of heart attack. Treatment will continue for up to 22 months, with monthly injections given under the skin.

During the study, doctors will monitor participants for major heart-related events including death from heart problems, another heart attack, or stroke. The study will also look at other outcomes such as the need for procedures to open blocked heart arteries, hospitalizations for heart failure, which is when the heart cannot pump blood well enough, and overall survival. The goal is to determine whether ziltivekimab can help prevent these serious complications in people who have experienced a heart attack and are at higher risk for future heart problems.

The study involves two groups of participants – one receiving rocatinlimab injections under the skin along with topical treatments, and another receiving placebo injections with the same topical treatments. The treatment period lasts for 24 weeks, during which the effectiveness of the medication will be evaluated by examining improvements in skin appearance and reduction in disease severity.

Throughout the study, doctors will monitor how well the treatment works by checking if participants’ skin becomes clearer and if their symptoms, such as itching and skin pain, improve. They will pay special attention to how the treatment affects different areas of the body, including the face and hands, in people who have atopic dermatitis in these locations.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The main purpose of this research is to determine if izalontamab brengitecan works better than standard chemotherapy treatments in patients who cannot receive certain types of immunotherapy treatments (anti-PD1/PD-L1). The study will measure how long patients live without their cancer getting worse and their overall survival time. During treatment, some patients may also receive pegfilgrastim, a supportive care medicine that helps the body make white blood cells.

The medications will be given in different ways – some through an intravenous infusion directly into a vein, while others, like capecitabine, are taken by mouth as tablets. The study will continue for several years to gather information about how well the treatments work and how safe they are for patients.

The treatment involves taking zipalertinib or placebo tablets by mouth, combined with chemotherapy medications given through an intravenous infusion. The chemotherapy drugs used in this study are cisplatin, carboplatin, and pemetrexed. These medications are commonly used to treat lung cancer after surgery to reduce the risk of cancer coming back.

During the study, participants will be randomly assigned to receive either zipalertinib tablets or matching placebo tablets. Neither the participants nor their doctors will know which treatment they are receiving. The treatment period may last up to 36 months, during which participants will receive regular medical check-ups to monitor their health and evaluate how well the treatment is working.

The purpose of the study is to determine if the three-medicine combination works better than the other treatments for reducing severe back pain. During the study, participants will take their assigned medication for 5 days. Some participants will receive the new combination treatment, while others will receive either Cataflam, Norgesic, or placebo.

The study will use tablets that look similar to ensure that neither the participants nor the healthcare providers know which treatment is being given. All medications will be taken by mouth. The study will measure how well each treatment reduces pain intensity and improves back movement. Throughout the study, participants will be monitored for any side effects that may occur from the medications.

The purpose of this research is to determine if the combination of trastuzumab deruxtecan with pembrolizumab works better than the standard treatment in controlling the disease. The medications will be given through an intravenous infusion, which means they are delivered directly into a vein. Trastuzumab deruxtecan is a type of medication that specifically targets cancer cells with high HER2 levels, while pembrolizumab helps the body’s immune system fight cancer cells.

During the study, participants will be randomly assigned to receive either the new combination treatment or the standard treatment. Their cancer will be monitored regularly using imaging scans to check how well the treatment is working. The doctors will continue to check the participants’ health and watch for any side effects throughout the study period.

The treatment plan involves giving medications before surgery (neoadjuvant therapy) to shrink the tumor. The study medications are given through an intravenous infusion directly into the bloodstream. Some participants will receive the new combination with sacituzumab tirumotecan, while others will receive standard chemotherapy which may include doxorubicin, epirubicin, or cyclophosphamide. All participants will also receive dexamethasone to help manage side effects, and some may receive capecitabine as part of their treatment.

The main purpose of this research is to determine whether the new treatment combination is more effective at eliminating cancer cells before surgery compared to standard chemotherapy. The study will also track how long participants remain free of cancer after treatment and monitor their overall survival. Researchers will carefully watch for any side effects and evaluate how the treatments affect participants’ quality of life.

The purpose of this research is to determine if AZD0780 can reduce the risk of serious cardiovascular events such as heart attacks, strokes, and problems with blood flow to the legs in people with cardiovascular disease. The medication will be tested in addition to patients’ regular cholesterol-lowering treatments.

During the study, participants will receive either AZD0780 or a placebo for up to 54 months. The study team will monitor participants for any cardiovascular events, including heart-related death, heart attacks, strokes, severe leg circulation problems, and emergency procedures to restore blood flow. Throughout the study, participants will continue their usual heart medications, including their regular cholesterol-lowering treatments.